Moderna Therapeutics has big ambitions and a bankroll to match. How a fledgling start-up became one of the most highly valued private drug firms ever.
Enjoying our latest content?
Login or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Zangi, L. et al. Nature Biotechnol. 31, 898–907 (2013).
Wolff, J. A. et al. Science 247, 1465–1468 (1990).
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Science 255, 996–998 (1992).
Warren, L. et al. Cell Stem Cell 7, 618–630 (2010).
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Immunity 23, 165–175 (2005).
Karikó, K. et al. Mol. Ther. 16, 1833–1840 (2008).
Karikó, K., Muramatsu, H., Keller, J. M. & Weissman, D. Mol. Ther. 20, 948–953 (2012).
Thess, A. et al. Mol. Ther. 23, S55 (2015).
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
mRNA-based therapeutics — developing a new class of drugs 2014-Sep-19
RNA interference rebooted 2014-Apr-22
Profile: Being Bob Langer 2009-Mar-04
Related external links
Rights and permissions
About this article
Cite this article
Dolgin, E. Business: The billion-dollar biotech. Nature 522, 26–28 (2015). https://doi.org/10.1038/522026a
Published:
Issue Date:
DOI: https://doi.org/10.1038/522026a
This article is cited by
-
Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells
BMC Biotechnology (2017)
-
Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia
Scientific Reports (2016)
